First Medicine Specifically Targeting BRCA Mutations to Demonstrate Statistically Significant Improvement in Invasive Disease-Free Survival in Adjuvant Setting Following Definitive Local Treatment and Neoadjuvant or Adjuvant ChemotherapyKENILWORTH, N.J. (BUSINESS WIRE) $MRK #MRK AstraZeneca and Merck (NYSE: MRK),.